Request Appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Intlekofer
Dr. Andrew Intlekofer is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 8 years. He is one of 505 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 60 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2015
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2011
Perelman School of Medicine at the University of PennsylvaniaClass of 2009
Certifications & Licensure
NJ State Medical License 2018 - 2027
NY State Medical License 2011 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Corrigendum to 'Systemic metabolic changes in acute and chronic lymphocytic choriomeningitis virus infection' [Mol Metab Volume 99 (2025) Article 102194].Caroline R Bartman, Shengqi Hou, Fabian Correa, Yihui Shen, Victoria da Silva-Diz
Molecular Metabolism. 2025-09-01 - Systemic metabolic changes in acute and chronic lymphocytic choriomeningitis virus infection.Caroline R Bartman, Shengqi Hou, Fabian Correa, Yihui Shen, Victoria da Silva-Diz
Molecular Metabolism. 2025-09-01 - Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.Rabeya Molla, Kurt Bantilan, Ellin Berman, Philip Caron, Lorenzo Falchi
Haematologica. 2025-08-07
Journal Articles
- Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface MutationsMartin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaAndrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Andrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Grant Support
- Targeting isocitrate dehydrogenase mutations by enzyme hyperactivationSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Targeting isocitrate dehydrogenase mutations by enzyme hyperactivationSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Metabolic control of normal and malignant hematopoiesisSLOAN-KETTERING INST CAN RESEARCH2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
